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1634pattern may not be as strongly inﬂuenced by a hormonal effect on
channel function.
A genome-wide association study recently suggested an intriguing
associated locus near the KCND3 (Kv4.3) gene, which encodes
a subunit of the Ito channel (5). The association was not signiﬁcant
genome-wide, and it did not replicate in other study populations.
Nevertheless, the biological plausibility of Ito channel involve-
ment in ER ECG formation seems to be more than a coincidence.
Future studies in this ﬁeld should perhaps focus on ﬁnding genetic
variants of the ER ECG pattern followed by a horizontal/down-
sloping ST-segment, which could highlight better the genetic
background of the ER syndrome.
The presence of an inferolateral ER ECG is affected by
testosterone level, which probably explains the male predominance
and the decline with aging of this ECG pattern. Furthermore, the
ER ECG pattern with a rapidly ascending ST-segment seems to be
the pattern most closely associated with testosterone level.*M. Juhani Junttila, MDy
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larization pattern. Heart Rhythm 2012;9:1627–34.Letters to the EditorHigher N-Terminal Pro–B-Type
Natriuretic Peptide May Be
Related toVeryDifferentConditions
We read the paper by Hijazi et al. (1) with interest. The authors
investigated the incremental value of measuring N-terminal pro–B-
type natriuretic peptide (NT-proBNP) levels in addition to estab-
lished risk factors (including the CHA2DS2VASc [heart failure,
hypertension, age 75 years and older, diabetes, and previous stroke
or transient ischemic attack, vascular disease, age 65 to 74 years, sex
category (female sex, respectively)] score) for the prediction of
cardiovascular and bleeding events. They concluded that NT-
proBNP levels are often elevated in atrial ﬁbrillation (AF) and
independently associated with an increased risk for stroke and
mortality. NT-proBNP improves risk stratiﬁcation beyond the
CHA2DS2VASc score and might be a novel tool for improved
stroke prediction in AF. The efﬁcacy of apixaban compared with
warfarin was independent of the NT-proBNP level.
Although most widely used as a marker of systolic heart failure,
elevated NT-proBNP has been reported in patients with diastolic
dysfunction (2). Therefore, it is important to determine diastolic
and systolic function by echocardiography. Performing echocardi-
ography also is important for measurement of pulmonary artery
pressure. Pulmonary arterial hypertension is common with rheu-
matic diseases, and NT-proBNP levels may be a result of the
increase in pulmonary pressure (3). On the other hand, high levels
of NT-proBNP can be seen in many conditions that increase
cardiac output and cardiac stress, such as sepsis, cirrhosis, and
hyperthyroidism (4). That is why determination of liver test results
and thyroid hormone proﬁle may reveal stronger results in such
a study.
NT-proBNP is an important prognostic factor for cardiovascular
diseases; however, besides cardiac diseases, elevated NT-proBNP
levels may be seen in several diseases. A prominent disease with
elevated NT-proBNP is a respiratory system disease, such as chronic
obstructive pulmonary disease, pulmonary embolism, and interstitial
lung disease, in which B-type natriuretic peptide levels are elevated
in response to the pressure of the right side of the heart (5). In
addition, cor pulmonale, secondary pulmonary hypertension, or
hypoxemia may represent important stimuli for the release of NT-
proBNP from the right side of the heart. Given that hypoxemia
alone is a risk factor for the development of AF, respiratory system
disorders should not be ignored in such a study.
Furthermore, Hijazi et al. (1) used the Cockcroft-Gault (CG)
equation to determine the glomerular ﬁltration rate (GFR).
However, the CG equation may measure a lower GFR in younger
age groups, and GFR can be higher in older individuals. Although
the Chronic Kidney Disease Epidemiology Collaboration recently
published an equation for GFR using the same variables (serum
creatinine level, age, sex, and race) as the CG equation, the Chronic
Kidney Disease Epidemiology Collaboration equation more accu-
rately categorized individuals with respect to long-term clinical risk
compared with the CG equation (6).
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1635Elevated NT-proBNP independently predicts all-cause mortality
and morbidity of patients with AF. However, higher NT-proBNP
levels may be associated with different conditions, and the pivotal
roles of those factors evaluate further large-scale, prospective
randomized clinical trials. In addition, measuring not only NT pro-
BNP, but also troponin T and I (7), is an easy method to assess
increased risk for stroke and mortality in patients with AF. These
markers might be useful in clinical practice. Finally, one should
keep in mind that NT-proBNP alone without other predictive
markers may not give exact information to clinicians about the
prognostic indication of patients; thus, NT-proBNP should be
evaluated along with other serum mortality predictive markers.*Sevket Balta, MD
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We thankDr. Balta and colleagues for their comments on our article
concerning the use of N-terminal pro B-type natriuretic peptide(NT-proBNP) for atrial ﬁbrillation (AF) in the ARISTOTLE
(Apixaban for the Prevention of Stroke in Subjects With Atrial
Fibrillation) trial (1). Of the 18,201 patients with AF in the
ARISTOTLE trial, 14,892 comprised the population in whom
baseline NT-proBNP plasma samples were analyzed. The results
showed that NT-proBNPwas strongly and independently related to
stroke, cardiovascular events, and mortality.
As Dr. Balta and colleagues point out, several states may affect
NT-proBNP levels (2,3). However, it is important to view this in
the context of the current study. Reversible causes of AF (e.g.,
infection, sepsis acute lung disease exacerbation, and thyrotoxicosis)
were excluded, and patients were generally stable at the time of
enrollment with regard to other medical illnesses (4). Moreover,
adjustments were performed with Cox proportional hazards models
for established risk factors, including heart failure, renal function,
and biomarkers of myocardial damage measured with troponin. It is
true that a large number of factors, including lung disease, will
contribute to elevation of NT-proBNP, and some of these no
doubt contributed to the pathophysiologic link of NT-proBNP
elevation and clinical events. Irrespective of the mechanism,
however, what we showed was that the information obtained
from NT-proBNP levels, in addition to the clinical risk factors,
provided independent prognostic information in the population
with AF.
It is well known that various equations used to estimate renal
function have their strengths and weaknesses, and we can reassure
Dr. Balta and colleagues that our ﬁndings were not dependent on
the Cockcroft-Gault formula because we used cystatin C as the
biomarker to reﬂect renal function. This newer marker of renal
function does not depend on age for estimating the glomerular
ﬁltration rate; moreover, it is a well-established marker of cardio-
vascular events (5,6).
At present, guidelines recommend screening of patients with
newly detected AF with echocardiography to identify underlying
structural pathologies and potential reversible causes of AF and to
tailor treatments. There are a large number of reported echocar-
diographic measures of diastolic function, including left atrial size,
that relate to stroke risk, but with little consensus as to how to
simply and reliably incorporate these into risk assessment.
However, for prediction of the risk of thromboembolic events,
a complementary measurement of NT-proBNP is attractive as an
easily available tool to provide further guidance on management.
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